US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Nektar Says Eli Lilly Botched Autoimmune Drug Trials

By Ayden Crosby · August 7, 2023, 7:47 PM EDT

Nektar Therapeutics is accusing Eli Lilly of butchering and delaying clinical trials for a new autoimmune-disease drug the two companies agreed to develop together, claiming the pharma giant ruined the drug's...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Nektar Therapeutics v. Eli Lilly & Co

Case Number

3:23-cv-03943

Court

California Northern

Nature of Suit

Contract: Other

Date Filed

August 07, 2023

Featured Stories

J&J $5.5B Talc MDL Deal, $25.4M Cooley Judgment And More No Photo Available

Gianna Ferrarin

Law360 Healthcare Authority looks at Johnson & Johnson's $5.5 billion commitment in a proposed settlement to resolve thousands of suit... (more story)

This Week's Healthcare Earnings: Tenet, CHS, AstraZeneca No Photo Available

Yeji Jesse Lee

Healthcare providers and drugmakers posted results for the second quarter of 2026 this past week, giving investors a closer look at ho... (more story)

340B Appellate Cases To Watch In The 2nd Half Of 2026 No Photo Available

Mark Payne

Drugmakers are pressing appellate judges in the back half of 2026 to strike down state laws blocking them from restricting 340B contra... (more story)